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Smad3 promotes cancer progression by inhibiting
E4BP4-mediated NK cell development
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TGF-b is known to inﬂuence tumour progression. Here we report an additional role of Smad3
in the tumour microenvironment regulating cancer progression. Deletion or inhibition of
Smad3 in the tumour microenvironment suppresses tumour growth, invasion and metastasis
in two syngeneic mouse tumour models. Smad3 / bone marrow gives rise to an expanded
NK cell population with enhanced tumour-suppressive activities in vivo, and promotes
differentiation of NK cells ex vivo. We identify E4BP4/NFIL3 as a direct Smad3 target
gene critical for NK cell differentiation. Smad3 suppresses transcription of IFN-g via E4BP4
in a T-bet independent manner. Therefore disruption of Smad3 enhances both the
E4BP4-mediated NK cell differentiation and anti-cancer effector functions in vivo and in vitro.
Furthermore, systemic treatment with a Smad3 inhibitor SIS3 effectively suppresses
cancer progression. In summary, suppression of NK cell-mediated immunosurveillance
via the Smad3-E4BP4 axis contributes to cancer progression. We propose targeting
Smad3-dependent tumour microenvironment may represent an effective anti-cancer strategy.
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C
ancer progression is dependent not only on the
characteristics of cancer cells but also on the tumour
microenvironment1,2. Transforming growth factor-b
(TGF-b) has been suggested to play a suppressive role in
carcinogenesis, but paradoxically cancer cells also produce
TGF-b1 to support the tumour development3–6. Cancer
cell-derived TGF-b can promote tumour growth by triggering
angiogenesis, epithelial–mesenchymal transition and the matrix
metalloproteinase (MMP) system for ECM degradation3–6. There
is an increasing evidence that pro-tumorigenic microenvironment
is promoted by TGF-b signalling7,8. Smad3 is a key mediator
of canonical TGF-b signalling pathway and plays an important
role in the TGF-b1-mediated transcriptional regulation9.
Smad3-deﬁcient mice exhibit impaired mucosal immunity and
diminished T-cell responses to TGF-b8,10. The lack of Smad3
resulted in severe graft-versus host disease by promoting Th1
differentiation and granulocyte-mediated tissue injury11. Smad3
can bind to the Foxp3 enhancer for the development of regulatory
T (Treg) cells and differentially regulates the induction of Treg
and Th17 immune responses12,13. Thus mice lacking Smad3 have
impaired Treg development14. TGF-b has a suppressive role in
the cytolytic activity, especially on the interferon responsiveness
of natural killer (NK) cells in vitro15,16. In addition, Trotta et al.17
elucidated that TGF-b/Smad3 signalling can suppress CD16-
mediated interferon-gamma (IFN-g) production in NK cells via
reducing T-bet expression. Smad3 mutant mice were reported to
develop metastatic colorectal cancer18, which may be related to
chronic inﬂammation19,20. In contrast, mice lacking Smad3 were
recently suggested to be resistant to chemical-induced skin
carcinogenesis by Li et al.21. The discrepancy among the
studies underlie the importance in further delineation of the
mechanism of TGF-b/Smad signalling in tumour progression.
Nevertheless, these studies suggested that Smad3 could be an
important checkpoint for TGF-b signalling in the tumour
microenvironment.
In the present study, we demonstrate the crucial role of
Smad3-dependent tumour microenvironment in cancer progres-
sion by using two well-established syngeneic mouse tumour
models. Mice lacking Smad3 are protected against tumour
growth, invasion, metastasis and death. NK cell population in
the Smad3 / tumour microenvironment is dramatically
expanded. This observation led us to identify that E4BP4 (Nﬁl3),
one of the master transcription factors for NK cell differentia-
tion22–24, is a direct Smad3 target gene. Thus TGF-b/Smad3
signalling facilitates cancer progression by suppressing NK cell
production via downregulating E4BP4. The crucial role of
Smad3 is further supported by animal experiments with re-
constitution of GFPþ Smad3 / bone marrow on Smad3þ /þ
mice and adoptive transfer of Smad3 / NK1.1þ cells into
B16F10 tumour-bearing NOD/SCID mice. Furthermore,
systemic treatment with a Smad3 inhibitor can suppress cancer
progression by reversing the tumour promoting to an anticancer
microenvironment in vivo. Therefore, our ﬁndings reveal the
unexplored role of Smad3 in NK cell immunity and tumour
microenvironment. The therapeutic potential of Smad3-targeted
therapy for cancer treatment is also implicated.
Results
Smad3 is essential for cancer progression in mice. As TGF-b/
Smad signalling has been shown to be a pro-tumorigenic factor in
cutaneous melanoma and lung cancer25,26, the role of Smad3
in tumour microenvironment was investigated by using two
syngeneic mouse tumour models with luciferase-expressing
invasive mouse lung carcinoma (LLC-luc) or melanoma
(B16F10-luc) established in Smad3 / (deletion of exon 8 and
disruption of exon 710) and their littermate Smad3þ /þ mice
(C57BL/6J background). During the ﬁrst week after subcutaneous
inoculation of LLC-luc cells, we observed almost equal tumour
growth in both Smad3 / and Smad3þ /þ mice. However,
in the subsequent weeks, signiﬁcant tumour regression was
found in Smad3 / mice where the tumours became
undetectable by macroscopic and microscopic examinations and
by bioluminescence imaging at week 3 (Fig. 1a–d). In contrast,
the tumours in the Smad3þ /þ mice grew rapidly and invasively,
resulting in 40% mortality at week 3 (Fig. 1a–d). A similar
pattern of cancer progression was observed in Smad3 / and
Smad3þ /þ mice bearing a highly invasive melanoma cancer
cell line B16F10 (Fig. 1e–g). In the B16F10 tumour-bearing
Smad3þ /þ mice, melanoma grew rapidly and invasively with
metastasis to the lymph nodes, lung and colon, resulting in
60% mortality at week 3 (Fig. 1h and Supplementary Fig. 1).
In contrast, these malignant features were absent in the
tumour-bearing Smad3 / mice in which survival rate was
100% without features of metastases (Fig. 1h and Supplementary
Fig. 1). In addition, the protective effect of Smad3 /
microenvironment was further conﬁrmed on a tumour
rechallenging model (Supplementary Fig. 2A,B). These
observations supported the importance of Smad3 in the tumour
microenvironment for promoting tumour growth, invasion and
metastasis. The supportive role of Smad3-dependent
microenvironment in cancer metastasis was further examined
in mouse metastatic models by intravenously (i.v.) administering
LLC-luc or B16F10-luc cells into the mice. As shown in Fig. 1i–n,
mice lacking Smad3 were resistant to cancer metastasis with
barely detectable LLC-luc cancer cells and a few melanoma
nodules in the lung. By contrast, Smad3þ /þ mice developed
massive lung cancer with a 100% mortality rate (Fig. 1o,p). These
ﬁndings provided a clear and direct evidence for a crucial role of
Smad3-dependent microenvironment in cancer progression.
Smad3 suppresses NK cell immunity in tumour-bearing mice.
We next investigated the underlying mechanisms whereby
mice lacking Smad3 were protected against cancer growth
and metastasis. A 10-fold increase in the number of tumour-
inﬁltrating NK1.1þ NKp46þ and NK1.1þ IFN-gþ NK cells
was found in the B16F10 tumour-bearing mice lacking Smad3
compared with the Smad3þ /þ group (Fig. 2a–c). The inhibitory
effect of Smad3-dependent microenvironment on NK cell
population was further investigated. Native Smad3 / mice
(without tumour inoculation) showed slight increase in mature
NK1.1þ CD49bþ NK cells in the bone marrow, spleen, lung and
peripheral blood compared with Smad3þ /þ mice
(Supplementary Fig. 3A). The population of NK1.1þ CD49bþ
NK cells was further increased after cancer inoculation, resulting
in a 10-fold increase in NK1.1þ CD49bþ NK cells in the
peripheral blood and lung and a 3-fold increase in the spleen
compared with the tumour-bearing Smad3þ /þ mice
(Supplementary Fig.3B,C). The increase in mature NK1.1þ
NKp46þ NK cells was also observed in the tumour, spleen and
blood of the B16F10-rechallenged mice lacking Smad3
(Supplementary Fig. 2C,D). In addition, deletion of Smad3 also
enhanced the anticancer activities of NK cells by increasing the
levels of granzyme B, interleukin (IL)-2 and IFN-g locally within
the cancer microenvironment and in the systemic circulation
(Fig. 2d,e). The splenic NK cells isolated from the B16F10
tumour-bearing Smad3 / mice also exhibited a signiﬁcant
increase in the ex vivo cytotoxicity against tumour cells with
higher levels of INF-g production when compared with the
NK cells obtained from the tumour-bearing Smad3þ /þ mice
(Supplementary Fig. 4). Moreover, a marked reduction in
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vascular endothelial growth factor (VEGF) expression, CD31þ
blood vessels, CD4þ Foxp3þ Treg cells and the expression
of MMP-2, MMP-9, MMP-13 and C-X-C motif chemokine
receptor 4 (CXCR4) in the tumour stroma were observed in the
Smad3 / tumour microenvironment (Supplementary Figs 5
and 6). In contrast, depletion of NK cells from the tumour-
bearing hosts with a neutralizing antibody restored rapid pro-
gression of the B16F10 tumour only in Smad3 / mice but not
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Figure 1 | Mice lacking Smad3 are protected from tumour progression. LLC-luc cancer cells were s.c. inoculated into Smad3þ /þ and Smad3 / mice
(n¼ 3) and examined by bioluminescence imaging on day 21 (a), tumour volumes (b), tumour weights on day 21 (c) and the Kaplan–Meier plot of survival
(d). B16F10 cells (2 106 cells per mouse) were s.c. inoculated into Smad3þ /þ and Smad3 / mice (n¼ 5) and examined for the growth patterns
(highlighted with white circles) on day 21 (e), tumour volumes (f), tumour weights on day 21 (g) and the Kaplan–Meier plot of survival (h). LLC-luc cells
(3 105 cells per mouse) were i.v. inoculated into Smad3þ /þ and Smad3 / mice (n¼ 5) and examined for the metastatic growth patterns in the lung
by bioluminescence imaging (i), quantitative photon intensities (j) and histology on H&E-stained sections (k). B16F10 cells (3 105 cells per mouse) were
i.v. inoculated in Smad3þ /þ and Smad3 / mice (n¼ 5) and examined for metastatic growth in the lung by macroscopic morphology (l), quantitative
analysis of metastatic nodules (m) and histology on H&E-stained sections (n). Note that the metastatic B16F10 tumours in the lung are shown by the
dark-black nodules grossly and the metastatic LLC or B16F10 nodules on H&E-stained sections are indicated with the white star (*). Kaplan–Meier plot of
survival rates of metastatic LLC-luc (o) and B16F10 (p) tumour-bearing mice. Data represent the mean±s.d. for groups of mice as indicated in individual
experiments above. *Po0.05, **Po0.01 compared with tumour-bearing Smad3þ /þ mice analysed by analysis of variance. Scale bars, 50mm.
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Figure 2 | Smad3 facilitates cancer progression by suppressing host NK cell immunity in the tumour microenvironment. (a) Immunoﬂuorescence
detects the tumour-inﬁltrating NK1.1þ , NKp46þ and NK1.1þ INF-gþ NK cells in the B16F10 tumour collected on day 7. Representative images of tumour
sections stained with the antibodies recognizing NK1.1 (green, upper panel), NKp46 (green, middle panel), NK1.1 (red) and IFN-g (green, lower panel) are
shown. Nuclei were counterstained with DAPI (blue), and the percentage of positive cells in the tumour tissues of Smad3 / or Smad3þ /þ mice are
shown (right panel). (b) Two-colour ﬂow cytometry shows the population of tumour-inﬁltrating NK1.1þ CD49bþ cells in the B16F10 tumour. (c) Western
blotting analysis detects the NKp46 expression within the tumour tissues. (d,e) Enzyme-linked immunosorbent assay analysis determines the levels of
granzyme B, IL-2 and IFN-g in the tumour tissues (d) and circulation (e). (f) Effects of NK cell depletion on cancer progression in B16F10 tumour-bearing
Smad3 / mice as determined by bioluminescent imaging, tumour volume measurement and the survival rate. Data represent mean±s.d. for groups of
3–5 mice. *Po0.05, **Po0.01 compared with B16F10 tumour-bearing Smad3þ /þ (a–e) or Smad3 / mice (f) analysed by analysis of variance.
Scale bars, 50 (upper panel in a) and 100mm.
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in Smad3þ /þ mice in vivo (Fig. 2f and Supplementary Fig. 7).
These ﬁndings suggested an inhibitory role of Smad3 in NK cell
development on a systemic level and a crucial role of NK cells in
the Smad3-dependent tumour microenvironment.
Smad3 tumour microenvironment is derived from bone marrow.
We then investigated the origin of Smad3-dependent tumour
microenvironment by using GFPþ Smad3 / and GFPþ
Smad3þ /þ bone marrow chimeric mice bearing subcutaneous
LLC-luc or B16F10-luc tumours. Our data showed that almost
all stromal cells within the tumour tissue were derived from
the transplanted bone marrow as recognized by their green
ﬂuorescent protein (GFP) expression (Fig. 3a). Compared with
GFPþ Smad3þ /þ chimeric mice, mice with GFPþ Smad3 /
bone marrow exhibited signiﬁcant reduction in the tumour
growth and mortality rate (Fig. 3b,c), which was again associated
with a 10-fold increase in GFPþ NK1.1þ cells in the tumour
microenvironment (Fig. 3a). These results suggested that Smad3
may suppress host anticancer immunity at the bone marrow
compartment. The inhibitory role of Smad3 on bone marrow-
derived NK cell immunity was conﬁrmed in vitro; the cancer-
killing activity of NK cells differentiated from Smad3 / bone
marrow cells was signiﬁcantly higher than the Smad3þ /þ con-
trol (Supplementary Fig. 8A). Interestingly, disruption of Smad3
(knockout or inhibition) facilitated NK cell maturation (NKp46þ
IFN-gþ cells) even in the presence of TGF-b1(Supplementary
Fig. 8C). Therefore, deletion of Smad3 may enhance NK
cell development in bone marrow and augmentation of host
anticancer immunity at the distant tumour microenvironment.
Smad3 suppresses E4BP4-dependent NK cell maturation.
As Smad3 / microenvironment was able to protect mice
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Figure 3 | Smad3-dependent tumour microenvironment is derived from the bone marrow. LLC-luc or B16F10-luc cancer cells were s.c. inoculated into
GFPþ Smad3þ /þ and GFPþ Smad3 / chimeric mice and examined for: (a) bone marrow-derived NK cells (GFPþ NK1.1þ ) in the tumour tissues by
two-colour immunoﬂuorescence; (b,c) tumour growth patterns by bioluminescent imaging, tumour volumes, tumour weights on day 21 and the survival
rate of LLC (b) or B16F10 (c) tumour-bearing chimeric mice. Data represent mean±s.d. for groups of 4–5 mice. *Po0.05, **Po0.01 compared with
tumour-bearing Smad3þ /þ chimeric mice received GFPþ Smad3 / bone marrow transplantation analysed by analysis of variance. Scale bars, 100mm.
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against cancer progression by dramatically increasing NK cell
production (Figs 1–3 and Supplementary Figs 1 and 2), we fur-
ther investigate the unexplored role of Smad3 as a negative reg-
ulator in the NK cell development. Western blottings showed that
deletion of Smad3 increased the expression of E4BP4 (or Nﬁl3),
an important transcription factor for NK lineage commitment22–
24, in both bone marrow-derived and splenic NK cells from the
Smad3 / mice on Day 10 after tumour inoculation (Fig. 4a). It
suggested a close link between Smad3 and NK cell development
in the tumour microenvironment. To examine the inhibitory role
of TGF-b/Smad3 signalling in E4BP4, total bone marrow cells or
untouched splenic NK cells from Smad3þ /þ or Smad3 /
mice were stimulated with TGF-b1 for 3 h and subjected for real-
time PCR analysis. As shown in Fig. 4b–d, TGF-b1 signiﬁcantly
suppressed the transcription of E4BP4 mRNA in Smad3þ /þ
bone marrow cells and splenic NK cells, which was blunted when
Smad3 was genetically deleted or pharmacologically inhibited
with Smad3 inhibitor (SIS3). We next investigated the functional
importance of E4BP4 in Smad3-mediated suppression of NK cell
development by transfecting bone marrow cells from Smad3þ /þ
and Smad3 / mice with nonsense (control) or short interfering
RNA (siRNA) against mouse E4BP4 (siE4BP4) and cultured
under NK cell differentiation medium for 6 days. Real-time PCR
detected that SIS3 treatment increased E4BP4 mRNA expression
in Smad3þ /þ NK cells, whereas transient knockdown with
siE4BP4 resulted in signiﬁcant inhibition of E4BP4 mRNA
expression in bone marrow-derived Smad3þ /þ and Smad3 /
NK cells as well as SIS3-treated Smad3þ /þ NK cells
(Supplementary Fig. 9). Strikingly, while the production of
CD244þ NKp46þ (immature NK cells) and CD244þ NKp46
(NK cell progenitors) cells was signiﬁcantly accelerated in
Smad3 / or SIS3-treated Smad3þ /þ bone marrow cells, this
promoting effect was diminished when E4BP4 was knocked down
(Fig. 4e,f), demonstrating the functional importance of E4BP4 in
the Smad3-mediated NK cell differentiation. Furthermore, a
conversed Smad3-binding site (SBS) was found within the 30 UTR
(untranslated region) of E4BP4 gene (Fig. 4g) by using ECR
browser (rVista 2.0, http://rvista.dcode.org/)27. The physical
binding of Smad3 on the UTR of E4BP4 gene was enriched by
TGF-b1 stimulation as shown by the results of chromatin
immunoprecipitation (ChIP) assay (Fig. 4h,i). Thus Smad3
transcriptionally inhibited E4BP4 in response to TGF-b1,
which was reversed when Smad3 is mutated as demonstrated
by the luciferase reporter assay (Fig. 4j). These ﬁndings
revealed the inhibitory role of Smad3 in NK cell development
via downregulating the transcription of its direct target
gene E4BP4. Given that deﬁciency of Smad3 prevents TGF-b1-
mediated inhibition of E4BP4 expression, targeting the
TGF-b1/Smad3–E4BP4 axis to accelerate the development of
NK cells may enhance their anticancer immunity within the
tumour microenvironment.
TGF-b1 suppresses NK cell immunity via Smad3–E4BP4 axis.
The speciﬁc role of Smad3 on NK cell-mediated antitumour
activities was further examined by adoptive transfer of
Smad3þ /þ or Smad3 / NK1.1þ cells into the B16F10
tumour-bearing NOD/SCID mice in which the NK cell
population was deﬁcient28. Noticeably, NOD/SCID mice that
received Smad3 / NK cells showed a greater inhibition of
tumour growth compared with those that received Smad3þ /þ
NK cells (Fig. 5a,b). Trotta et al.17 recently reported of suppressed
CD16-mediated IFN-g production of NK cells by TGF-b1 via
Smad3–T-bet-dependent pathway, so we compared the relative
impact of E4BP4 versus T-bet on Smad3-mediated NK cell
antitumour activities by adoptive transfer of the Smad3 / NK
cells with or without knockdown of E4BP4 (Nﬁl3) or T-bet into
the B16F10 tumour-bearing NOD/SCID mice. Interestingly,
mice that received E4BP4 knockdown Smad3 / NK cells
(siE4BP4) exhibited a higher tumour growth rate, which was
associated with lower levels of inﬁltrating NK1.1þCD3 NK
cells and the expression of NKp46 when compared with those
that received siT-bet Smad3 / NK cells (Fig. 5c,d). In vitro
study also conﬁrmed this observation that NK differentiation
and IFN-g expression were more signiﬁcantly inhibited by
knockdown of E4BP4 compared with that in T-bet knockdown
Smad3 / NK cells (Fig. 5e). A direct E4BP4-binding site on the
promoter of IFN-g (which is 208 nt apart from the T-bet-binding
site) is predicted by ECR browser and therefore the results
supporting that knockdown of E4BP4 suppressed IFN-g
expression in a T-bet-independent manner (Supplementary
Fig. 10).
Targeting Smad3 protects against cancer progression. The
encouraging ﬁndings from tumour-bearing Smad3 / mice
leads us to further test a hypothesis that targeting Smad3-
dependent tumour microenvironment may protect mice against
cancer progression. This was examined on Smad3þ /þ mice
bearing B16F10 or LLC tumours by inactivating Smad3 signalling
with an inhibitor SIS3 that speciﬁcally blocks the phosphorylation
and DNA binding of Smad3 proteins29. The systemic treatment
of SIS3 signiﬁcantly inhibited the phosphorylation of Smad3 in
both LLC and B16F10 tumour tissues and suppressed cancer
progression in a dosage-dependent manner, resulting in a 100%
survival rate (Figs 6a–d and 7a and Supplementary Figs 11A–D
and 12A). More importantly, SIS3 treatment signiﬁcantly
increased NK cell production in a dose-dependent manner,
showing up to a ﬁvefold increase in NKp46þ cells in tumour
tissues (Fig. 6e). Inhibition of Smad3 also enhanced anticancer
activities of NK cells by increasing releases of granzyme B, IL-2
and IFN-g locally within the tumour tissues and systemically in
the circulation (Fig. 6f,g). Depletion of NK cells from SIS3-treated
B16F10 tumour-bearing mice partially reversed the antitumour
effects of SIS3 (Supplementary Fig. 13), which further supports
the promoting role of Smad3-mediated NK suppression in cancer
progression. In vitro study also conﬁrmed this ﬁnding that
pharmacological inhibition of Smad3 signalling with a SIS3 was
capable of enhancing cancer-killing activities in both bone
marrow-derived or splenic NK cells (Supplementary Fig. 8A,B).
We demonstrated that the enhanced NK cell-mediated anticancer
immunity has an important role in the anticancer effects of
Smad3-dependent tumour microenvironment targeted treatment.
Furthermore, systemic treatment of SIS3 also signiﬁcantly altered
the tumour-friendly microenvironment, including suppression on
angiogenesis (VEGF expression and CD31þ vessels) and
tumour-invasive factors (MMP-2, MMP-9, MMP-13 and
CXCR4) (Fig. 7b–d, Supplementary Fig. 12B–D). In vitro
treatment with SIS3 was also able to inhibit the proliferation of
B16F10 melanoma cells in a dose-dependent manner
(Supplementary Fig. 14) and this may also suggest a direct
inhibitory effect of SIS3 on tumour cell growth. Taken together,
our results revealed that targeting Smad3-dependent
microenvironment may represent a novel and effective therapy
for invasive cancer.
Discussion
TGF-b has a supportive role in progression of established tumour
and Smad3 is a key mediator in the canonical TGF-b signalling
pathway. However, the potential role of Smad3 in the TGF-b1-
dependent tumour microenvironment remains incompletely
characterized. In this study, we demonstrated that Smad3 is
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essential for TGF-b1-mediated cancer progression, as both
genetic deletion and pharmacological inhibition of Smad3
produced a signiﬁcant inhibition of cancer growth, invasion
and metastasis, resulting in a markedly improved survival rate in
mouse models of LLC lung cancer and B16F10 melanoma.
Increase in production and anticancer activities of NK cells but
decrease in angiogenesis, Treg response and tumour-invasive
activities were found in the Smad3-knockout or -inhibited
tumour-bearing mice. It is suggested that TGF-b1-mediated
pro-tumorigenic microenvironment can be shifted into a
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tumour-suppressive one by targeting the Smad3-dependent
tumour microenvironment. We demonstrated that Smad3
is an important checkpoint for TGF-b-mediated cancer
progression in the tumour microenvironment. Therefore, target-
ing Smad3-dependent tumour microenvironment may represent
a novel and effective anticancer therapy.
Several mechanisms may be associated with the promoting
effect of Smad3-dependent microenvironment on cancer
progression, including angiogenesis, Treg response and tumour-
invasive factors, as well as availability of NK cells. We found
that genetic deletion or pharmacological inhibition of Smad3
signiﬁcantly enhanced the production of NK cells (NK1.1þ /
NKp46þ cells) locally in the tumour microenvironment and
systemically in the peripheral blood and splenic tissue. The effect
of Smad3 / microenvironment on NK cell production was
conﬁrmed on a B16F10-rechallenged model, where increased
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NK1.1þ NKp46þ NK cells were observed in the tumour tissue,
blood and spleen of rechallenged Smad3 / mice compared
with the rechallenged Smad3þ /þ control. These novel ﬁndings
suggest that TGF-b may act via a Smad3-dependent mechanism
to facilitate cancer progression by suppressing NK cell produc-
tion. This was further conﬁrmed by in vitro ﬁnding that deletion
of Smad3 also enhanced the production of NKp46þ IFN-gþ NK
cells from bone marrow cells. The critical role of NK cell
immunity in Smad3-dependent tumour microenvironment was
further demonstrated by depleting NK cells from tumour-bearing
Smad3 / mice with a neutralizing anti-NK1.1 antibody to
restore the aggressive progression of melanoma. However, the use
of anti-NK1.1 antibody may also deplete NKT cells; therefore, the
speciﬁc role of Smad3 in NK cell production was further
examined by adoptive transfer of Smad3 / or Smad3þ /þ NK
cells (NK1.1þ ) into the tumour-bearing NK cell deﬁciency mice
(NOD/SCID). We demonstrated an enhanced anticancer effects
of Smad3 / NK cells in cancer progression whereby mice
infused with Smad3 / NK1.1þ cells displayed reduced tumour
growth compared with Smad3þ /þ NK1.1þ cell-recipient mice.
It has been reported that TGF-b can inhibit NK cell-mediated
anticancer immunity, including maturation, cytotoxicity, IFN-g
production and the expression levels of activating receptors
NKG2D and NKp46 (refs 15–17,30–34). TGF-b can also suppress
CD16-mediated NK cell IFN-g production and antibody-
dependent cellular cytotoxicity in human NK cells via Smad3
(refs 17). Our ﬁndings reveal an unexplored role of Smad3 in the
suppression of NK cell production and activities. Results from
this study may also provide insights to explain the observation
that NK cell development and activities are largely impaired in
patients with cancer34–36.
Another novel ﬁnding from this study was that TGF-b1 can
directly inhibit the NK cell immunity via a Smad3–E4BP4 axis
and facilitate the cancer progression. E4BP4 (NFIL3) is one
of the important master transcription factors for NK cell
differentiation22–24. Here we found that TGF-b1 downregulated
E4BP4 expression in the bone marrow- and spleen-derived NK
cells in a Smad3-dependent manner, whereas genetic deletion or
pharmacological inhibition of Smad3 successfully inhibited
the TGF-b1-mediated E4BP4 suppression in NK cells. More
importantly, we identiﬁed that E4BP4 is a direct Smad3 target
gene. The conserved SBS located in the UTR of E4BP4 gene was
validated by ChIP assay. Smad3 could physically bind to the
E4BP4 gene and negatively regulate its transcription in response
to TGF-b1, which was further conﬁrmed by the real-time PCR
and luciferase reporter assays. The Smad3-mediated suppression
of E4BP4 was functionally important not only in NK cell
development but also in the cancer-killing activity. Knockdown of
E4BP4 decelerated the differentiation of both CD244þ NKp46þ
(immature NK cells) and CD244þ NKp46 (NK cell
progenitors) and also reduced the expression of INF-g of NK
cells from either Smad3 / or Smad3þ /þ bone marrow cells.
Interestingly, comparing to the study with transfer of Smad3 /
T-bet knockdown NK cells, adoptive transfer of Smad3 /
E4BP4 knockdown NK cells signiﬁcantly promoted tumour
growth in NOD/SCID mice with lower levels of IFN-g
production. This suggested that E4BP4 may be a more
important transcriptional factor than T-bet in NK cell
development and functions. The ability of adoptive transfer of
E4BP4 knockdown Smad3 / NK cells to reverse the
suppressive effect of Smad3 / NK cells on tumour growth in
B16F10 tumour-bearing NOD/SCID mice revealed the speciﬁc
role of E4BP4 in NK cell-mediated antitumour activities. This
ﬁnding is consistent with a previous study that deletion of T-bet
did not alter the IFN-g expression by NK cells in response to
parasitic infection37. A direct E4BP4-binding site can be predicted
on the promoter of IFN-g and the transcription of IFN-g can be
reduced in Smad3 / NK cells by E4BP4 knockdown in a T-bet
independent manner. Therefore, it is suggested that E4BP4 may
be one of the possible candidates of T-bet-independent pathway
for Smad3-mediated NK cell immunity. Our study demonstrated
that Smad3-mediated inhibition of E4BP4 transcription may be a
critical mechanism by which deletion of Smad3 promotes NK
cell immunity and suppresses cancer progression. Nevertheless,
further investigations should be done to conﬁrm the T-bet
independent pathway of TGF-b/Smad3-mediated suppression on
NK cell immunity.
Interestingly, we found that a majority of NK cells in the
Smad3 / tumour microenvironment originated from bone
marrow, as signiﬁcant induction of GFPþ NK1.1þ NK cells
was observed in the tumour tissues of the chimeric GFPþ
Smad3 /mice. Bone marrow is a primary site for NK cell
development, and it offers the cellular substrates and soluble
factors required for NK cell maturation38. NK cells can migrate
from the bone marrow to peripheral lymphoid organs, such
as the spleen and lymph nodes38. NK cells exert promising
anticancer activity, which may be circumvent by tumour-friendly
microenvironment via TGF-b/Smad3 signalling as deﬁned in the
present work. In line with this notion, we found that cancer
cells (B16F10 and LLC) proliferated at the same rate in both
Smad3þ /þ and Smad3 / mice during the ﬁrst week after
tumour implantation, but the progression was dramatically
inhibited in the Smad3 / mice from week 2 onwards. This
interesting phenomena implies that the host anticancer
immunity, presumably NK cells derived from bone marrow,
was exclusively suppressed in the Smad3þ /þ mice after the
tumour was fully established; but this suppressive effect
can be abolished when Smad3 was deleted or inhibited in the
tumour microenvironment. This may explain the dramatic
increase in GFPþ NK1.1þ NK cells at the tumour stroma of
the GFPþ Smad3 / chimeric mice. These ﬁndings also
indicate that NK cell development can be strongly suppressed
in the bone marrow compartment of Smad3þ /þ
microenvironment during cancer progression, but it can be
restored if Smad3 is eliminated. Thus Smad3 may function
as a determining factor for NK cell development in the bone
marrow, possibly via the TGF-b1/Smad3–E4BP4 axis as
discovered in this study.
Besides the enhanced NK cell immunity, we also observed that
upregulation of angiogenesis markers (for example, VEGF and
CD31þ vessels) and cancer invasive and metastatic proteins (for
example, MMP-2, MMP-9, MMP-13 and CXCR4) were largely
inhibited in the tumour microenvironment of Smad3 / mice
and in Smad3þ /þ mice treated with SIS3. These ﬁndings were
consistent with the reported properties of TGF-b/Smad3 signal-
ling in the induction of VEGF and MMP expression39,40. It is well
documented that both angiogenesis and cancer invasive and
metastatic activities play a critical role in cancer progression41–43.
Therefore, inhibition of angiogenesis and tumour-invasive
activities may account for the additional anticancer mechanism
by disrupting Smad3 in the tumour microenvironments.
Furthermore, inhibition of CD4þ Foxp3þ Treg cells could be
another mechanism associated with enhanced NK cell immunity
in the tumour-bearing Smad3 / mice. It is well accepted that
Smad3 is an important transcriptional factor that binds to Foxp3
and facilitates Treg development12,13. It is also reported that
Treg cells within the tumour microenvironment can suppress
cytotoxicity of NK cells, which is reversed by Treg targeted
treatment44,45. Thus it is likely that enhancement of NK cell-
mediated anticancer immunity may be associated with inhibition
of Treg cells in the Smad3 / tumour microenvironment.
However, the precise mechanism needs to be further investigated.
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Moreover, the present study also demonstrated that targeting
Smad3-dependent microenvironment may represent a novel and
effective anticancer therapy. By using a SIS3 that speciﬁcally
inhibits phosphorylation, DNA binding and protein interaction
of Smad329, we demonstrated that systemic treatment with SIS3
(2.5, 5, 10mg g 1, intraperitoneal (i.p.), daily) successfully
blocked the Smad3 activation in the tumour microenvironment
and signiﬁcantly suppressed the tumour growth and invasion and
associated with a 100% overall survival rate in the B16F10
and LLC tumour-bearing Smad3þ /þ mice. In line with the
observations in the Smad3 / mice, SIS3 treatment also
markedly enhanced the development and anticancer activities of
NK cells via a E4BP4-dependent mechanism. This was supported
by the ﬁnding that SIS3 treatment was capable of increasing
E4BP4 expression in Smad3þ /þ bone marrow and NK cells and
reversed the suppressive effect of Smad3 on NK cell development.
In addition, the suppressive effect of SIS3 on cancer progression
was also associated with inhibition of angiogenesis (CD31 and
VEGF) and tumour-invasive and metastatic activities, including
the expression of MMP-2, MMP-9, MMP-13 and CXCR4. It is
also possible that direct cytotoxicity of SIS3 on cancer cells
in vitro may account for an additional antitumour effect of SIS3
in vivo. The ﬁndings suggested SIS3 as a potential checkpoint
inhibitor for cancer. Thus systemic Smad3-targeted therapy may
represent a novel and effective therapeutic strategy for invasive
cancer.
In conclusion, Smad3-dependent tumour microenvironment
plays a crucial role in cancer growth, invasion and metastasis.
TGF-b establishes its tumour-friendly microenvironment by
suppressing NK cell production and cancer-killing activity via a
Smad3–E4BP4 axis. Our ﬁndings suggest that modulating the
TGF-b-dependent tumour microenvironments by targeting
Smad3 may represent an effective anticancer therapy.
Methods
Establishment of LLC-luc and B16F10-luc tumour cell lines. The murine lung
adenocarcinoma LLC (CRL-1642, ATCC) and melanoma B16F10 (CRL-6475,
ATCC) cells were cultured in DMEM supplemented with 10% heat-inactivated FCS
(GIBCO-BRL), 1 mM sodium pyruvate, 2mM glutamine, 100Uml 1 penicillin G
and 100mgml 1 streptomycin. The luciferase overexpression stable cell lines
of LLC-luc and B16F10-luc were established by transfection of pRRL-CMV
lentiviral-luciferase vector into the cancer cells, followed by clone selection.
Syngeneic mouse tumour models. Littermate Smad3 / (deletion of exon 8
and disruption of exon 7) or Smad3þ /þ mice on C57BL/6J (H-2b) background
(both sexes, aged 6–8 weeks, 20–25 g) were kindly provided by Dr Chuxia Deng10
and were used in this study. Two syngeneic mouse tumour models were induced in
Smad3 / and Smad3þ /þ mice by subcutaneously (s.c.) inoculating 2 106
LLC-luc or B16F10-luc cells (both from C57BL/6J mice) into the right ﬂank of the
mouse. For tumour rechallenge model, ﬁrst B16F10 tumour were induced in
Smad3 / and Smad3þ /þ mice by s.c. inoculating 1 106 B16F10-luc cells into
the left ﬂank of the mice, and the established tumours were surgically removed on
Day 15. Three weeks after, second B16F10 tumours (1 106 cells per mice, s.c.)
were induced on the right ﬂank of the same mice, tumour volumes were monitored
and samples were collected on Days 15 and 20 for further analysis according to
the protocol of Zaharoff et al.46. For metastasis study, 3 105 of LLC-luc or
B16F10-luc cells were i.v. administered into Smad3 / and Smad3þ /þ mice. The
number and volume of surface nodules of B16F10 melanoma (dark black) in the
lung of each mouse were counted, while LLC-luc tumours were observed by
bioluminescence imaging with IVIS Spectrum system (Caliper, Xenogen).
The photon intensity from speciﬁc regions was quantiﬁed by using the Living
Imaging software 4.2 (PerkinElmer). The tumour size was monitored every week
with a Vernier caliper and tumour volume was calculated by the formula:
V (in mm3)¼ 0.5(ab2), where a is the long diameter and b is the short diameter as
previously described47. The raw data underlying the tumour volume measurements
are shown in Supplementary Data 1. Mice were observed daily for the weight loss,
distress, food intake and activities. Mice were killed before the end point if 420%
weight loss occurred or the tumour reached the maximum permitted size
(2,000mm3), but experiments could be extended under veterinary supervision
under special circumstances, for example, if tumours grew faster than expected.
The speciﬁc experimental approach and the data obtained have been reviewed by
the Animal Ethics Experimental Committee at the Chinese University of Hong
Kong and conﬁrmed to be in accordance with local regulations. The survival rate
was recorded over the entire experimental period and converted into prolonged
survival following the Kaplan–Meier method48. All experimental procedures were
approved by the Animal Ethics Experimental Committee at the Chinese University
of Hong Kong (No. 13/049/GFR).
Tumour model in GFP-expressing bone marrow chimeric mice. To determine
the origin and role of Smad3-dependent tumour microenvironments in cancer
progression, GFPþ Smad3 / and GFPþ Smad3þ /þ bone marrow-chimeric
mice were generated by cross-breeding Smad3þ / C57BL/6J mice with GFP
transgenic C57BL/6J mice. A lethal irradiation (1500 cGy, Cs-irradiator) were
applied on Smad3þ /þ mice for bone marrow depletion and then 5 106 of bone
marrow cells from the GFPþ Smad3 / or GFPþ Smad3þ /þ mice were i.v.
administered into each mice 3 days after irradiation. The establishment of bone
marrow chimera was conﬁrmed at week 6 by ﬂow cytometry analysis with 95% of
peripheral blood cells being GFPþ cells. We then induced mouse tumour models
in GFPþ Smad3 / and GFPþ Smad3þ /þ mice by s.c. inoculating 2 106
LLC-luc or B16F10-luc cells into the right ﬂank of the mouse as described above.
The raw data underlying the tumour volume measurements are shown in
Supplementary Data 1. The animals were observed daily and the tumour size
and survival rate were measured as described in the section on syngeneic
tumour models. The experimental procedures were approved by the Animal
Ethics Experimental Committee at the Chinese University of Hong Kong
(No. 13/049/GFR).
NK cell depletion and adoptive transfer models. For depletion of NK cells,
Smad3þ /þ and Smad3 / mice were pretreated with the anti-NK1.1 (PK136,
BioXCell) or immunoglobulin G1 (IgG1) as negative control antibody (200 mg per
mouse, i.p.) at Day  1. Then B16F10-luc cells (2 106 cells) were s.c. inoculated
into groups of ﬁve mice with or without NK1.1þ cell depletion on Day 0, followed
by three additional antibody treatments (200 mg per mouse, i.p., weekly). The
efﬁciency of NK cell depletion was conﬁrmed with the absence of CD49bþ cells
(staining with anti-CD49b antibody, DX5, eBioscience) by ﬂow cytometric analysis
of small blood samples collected from the tail vein of antibody-treated mice.
To determine the speciﬁc role of Smad3-dependent NK cell antitumour
activities, a B16F10 tumour-bearing NOD/SCID mouse model49,50 was adoptively
transferred with Smad3þ /þ or Smad3 / NK cells (NK1.1þ ). Brieﬂy, B16F10
cells (1 106 cells) were inoculated s.c. into groups of three NOD/SCID mouse in
which both NK and NK T cells are deﬁcient. After tumour establishment on Day 5,
Smad3þ /þ NK1.1þ or Smad3 / NK1.1þ cells (5 106 cells) were infused i.v.
into the B16F10 tumour-bearing NOD/SCID mouse every 5 days with IL-2
supplement (i.p., 1,000U per mouse) every 2 days for examining tumour growth
and NK cell antitumour activities on Day 10.
In addition, we also compared the relative antitumour activities of E4BP4 versus
T-bet-dependent NK cells by adoptive transfer of siE4BP4-Smad3 / NK1.1þ or
siT-bet-Smad3 / NK1.1þ NK cells (5 106 cells) into B16F10 tumour-bearing
NOD/SCID mice as described above for examining tumour growth and NK cell
antitumour activities. The raw data underlying the tumour volume measurements
are shown in Supplementary Data 1. The animals were observed daily and the
tumour size and survival rate were measured as described in the section on
syngeneic tumour models. All experimental procedures were approved by
Animal Ethics Experimental Committee at the Chinese University of Hong Kong
(No. 13/049/GFR and 13/025/MIS).
SIS3 treatment. The tumour-bearing Smad3þ /þ mice were randomly divided
into four groups (n¼ 8 each group) on Day 7 after LLC-luc or B16F10-luc cancer
cell (s.c.) inoculation. SIS3 (S0447, Sigma) at different dosages (2.5, 5 or 10 mg g 1,
i.p., daily) were administered into the mice for 2 weeks, whereas control group were
received solvent control (0.05% dimethyl sulfoxide) instead. Tumour size was
monitored with a Vernier caliper every 2 day during the treatment. All mice were
subjected to bioluminescence imaging and then killed after the survival rate was
recorded on 15 days after SIS3 treatment. To determine the role of NK cells in
SIS3-mediated tumour suppression, NK cell depletion was done on SIS3-treated
mice and compared the result with SIS3-treated IgG control group on Day 15.
The tumours were isolated, weighted and photo-recorded. Tumour tissues were
collected for further analysis. The raw data underlying the tumour volume
measurements are shown in Supplementary Data 1. The animals were observed
daily and the tumour size and survival rate were measured as described in the
section on syngeneic tumour models. All experimental procedures were approved
by Animal Ethics Experimental Committee at the Chinese University of Hong
Kong (No. 13/025/MIS).
NK cell isolation. Splenic and bone marrow NK cells of the tumour-bearing mice
were harvested by passing the cells through a 40 mm nylon mesh to produce a
single-cell suspension. Erythrocyte contamination was eliminated by using RBC
lysis buffer (Sigma) and the NK cells were isolated by using the NK Cell Isolation
Kit II (Miltenyi Biotec), which provided 90–95% purity of NK cells as determined
by ﬂow cytometry with CD3 CD49bþ cells.
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Flow cytometric analysis. For quantitative analysis of NK cell populations, tissue
samples of the tumour-bearing mice were mechanically dissociated in chilled PBS
(supplemented with 3% BSA) and gently mashed through a 40-mm nylon mesh to
produce a single-cell suspension. NK cell populations were analysed with a ﬂow
cytometer by staining with Alexa 488-conjugated anti-mouse CD49b (DX5,
eBioscience), PE-conjugated anti-mouse NK1.1 (PK136, eBioscience),
Cy3-conjugated anti-mouse NKp46 (bs-2417R-cy3, Bioss) and PE-conjugated
anti-mouse CD244 (12-2441-83, eBioscience) antibodies. For IFN-g analysis,
NK cells (1 106) were cultured in the presence of 2 mM monensin (eBioscience)
and then ﬁxed and stained intracellular IFN-g (eBioscience) for 5 h. The samples
were subjected to acquire on FACSCalibur (Becton Dickinson) and analysed with
the WinMDI 2.9 software and Cytobank platform (cytobank.org).
NK cell cytotoxicity assay. The anticancer activity of NK cells was evaluated by
using a Cella-Tox Bioluminescence Cytotoxicity Assay Kit (Cell Technology Inc.).
In brief, isolated splenic NK cells from the tumour-bearing Smad3 / or
Smad3þ /þ mice were incubated with the NK-sensitive target cells (YAC-1),
syngeneic LLC or B16F10 cells at ratios of 1.25:1, 2.5:1, 5:1, 10:1 and 20:1,
respectively. In addition, splenic NK cells isolated from normal Smad3þ /þ mice
activated by 500Uml 1 IL-2 for 3 days with or without SIS3 treatment or Day  8
Smad3 / or Smad3þ /þ (with or without SIS3 treatment) bone marrow-derived
NK cells were incubated with B16F10 cells. After 4-h incubation at 37 C,
cytotoxicity signals were detected by a luciferase bioluminescence method, and
results were calculated according to the manufacturer’s instructions.
Western blotting analysis. Total proteins of tumour or normal (the skin of the
same mouse) tissues were extracted by chilled RIPA lysis buffer (Pierce) and then
subjected to the western blotting analysis with primary antibodies against CD31,
VEGF, MMP-2, MMP-9, MMP-13, CXCR4, NKp46, p-Smad3, Smad3 (all from
Santa Cruz Biotechnology) and E4BP4 (Cell Signaling) in 1:1,000, followed by
incubation with the corresponding IRDyeTM800-conjugated secondary antibodies
(1:10,000, Rockland Immunochemicals). b-Actin was used as an internal control.
Expression levels of the proteins were detected by using LiCor/Odyssey infrared
image system (LI-COR; Biosciences), and the band intensities were quantiﬁed with
the Image J software (version 1.48, NIH, Bethesda). Images have been cropped for
presentation; their full size images are presented in Supplementary Figs 15–20.
Histology and immunohistochemistry. For immunohistochemistry, tumour
tissues embedded in Optimal Cutting Temperature were cut into 6 mM sections
and stained with the speciﬁc antibodies. The microvessels of tumour tissues were
detected by anti-mouse CD31 antibody (BD Pharmingen) with Alexa Fluor
488-conjugated secondary antibody (Invitrogen), and the results were quantiﬁed as
microvessel densities according to the method of Weidner et al.51. Treg cells in the
tumour tissues were detected by immunoﬂuorescence with ﬂuorescein
isothiocyanate (FITC)-conjugated anti-CD4 and Cy3-conjugated anti-Foxp3
antibodies (eBioscience). NK cells were identiﬁed by anti-mouse NK1.1 (PK136;
R&D) and NKp46 (R&D) antibodies, while IFN-g expressing NK cells were
determined with Cy3- or APC-conjugated anti-NK1.1, FITC-conjugated
anti-NKp46 and FITC- or APC-conjugated anti-IFN-g antibodies (eBioscience).
All antibodies were 1:100 in dilution. Cell nuclei were counterstained with DAPI
(4,6-diamidino-2-phenylindole; Sigma). Positive cells and total cell counts from 10
high-power-ﬁeld ( 40) tumour tissues were scored and expressed as a percentage
of positive cells for each animal.
Enzyme-linked immunosorbent assay. Levels of plasma and intratumoural
granzyme B, IL-2 and IFN-g were determined by using the commercial enzyme-
linked immunosorbent assay kits (eBioscience). To collect the intratumoural tissue
ﬂuids, the chilled PBS was added into each tumour tissue samples in a ratio of
100mg tissue per ml. The tissues were then homogenized and centrifuged at
14,000 r.p.m. at 4 C for 10min. The collected tumour tissue solutions and blood
plasma were subjected for determination of NK cell activities, including granzyme
B, IL-2 and IFN-g, following the manufacturer’s instruction.
RNA extraction and real-time PCR. Total RNA was isolated from the cells using
the RNeasy Isolation Kit (Qiagen, Valencia, CA) according to the manufacturer’s
instructions. Real-time PCR was performed using Bio-Rad iQ SYBR Green
supermix with Opticon2 (Bio-Rad, Hercules, CA) as described previously52. The
primers used in this study included: E4BP4 forward 50-CAGTGCAGGTGACGA
ACATT-30 and reverse 50-TGTTCCACCACACCTGTTTTGA-30; and GAPDH
(glyceraldehyde 3-phosphate dehydrogenase) forward 50-GCATGGCCTTCCGTG
TTC-30 and reverse 50-GATGTCATCATACTTGGCAGGTTT-30. The ratio for
E4BP4 expression was normalized with GAPDH and expressed as the
mean±s.e.m.
siRNA knockdown. Smad3 / and Smad3þ /þ bone marrow cells were
harvested and transfected with (100 nM) nonsense control (siN05815122147,
RIBOBIO) and siRNA against E4BP4 (50-GAUGAGGGUGUAGUGGGCAAGU
CUU-30) on Days 0 and 4 as described previously53. The bone marrow cells were
ex vivo differentiated into NK cells according to the protocol of Fathman et al.54.
For adoptive transfer studies in NOD/SCID mice model, the ex vivo differentiated
NK cells were transfected with nonsense control, siRNA against E4BP4 or T-bet
(50-GGGAGAACUUUGAGUCCAU-30) on Day 5. The cells were collected on Day
6 (for Fig. 7) or Day 7 (for NK cell infusion, Supplementary Fig. 5). The maturation
and cytotoxicity of NK cells were quantiﬁed by ﬂow cytometry according to the
CD244, NK1.1, NKp46 or IFN-g expression proﬁles with directed dye-conjugated
anti-mouse antibodies (eBioscience).
MTT (methyl-thiazoldiphenyl tetrazolium) assay. The MTT assay was used to
determine the antiproliferative activity of SIS3 on B16F10 cells in vitro. In brief,
cancer cells (1 104 per well) were seeded on a 96-well plate and serial con-
centrations of SIS3 (0, 2.5, 5, 10, 15, 20 mM) were added on the next day. After 24-h
of SIS3 treatment, 30ml of MTT (5mgml 1) was added to each well and incubated
for 2 h at 37 C. The MTT solution was then replaced by 100ml of dimethyl
sulfoxide in each well and measured with a microtitre-plate reader (Bio-Rad) at
540 nm, and all data were calculated as a percentage against the control.
ChIP assay. ChIP was performed by using the SimpleChIP Enzymatic Chromatin
IP Kit (magnetic beads; Cell Signaling) according to the manufacturer’s instruc-
tions. In brief, bone marrow cells were isolated from Smad3þ /þ mice pretreated
with 1 ngml 1 TGF-b1 for 2 h and then isolated by the Kit (Cell Signaling).
Immunoprecipitation was performed with the antibody against Smad3 (1:100) and
IgG was used as a control (Cell Signaling). Precipitated DNAs were identiﬁed by
PCR using speciﬁc primers that detect the binding of Smad3 to 30 UTR of mouse
E4BP4 gene: forward 50-CCTCTGACACATCGGAGAGC-30 and reverse 50-CGG
AGAACAAGCTGATCGCCCT-30 .
Luciferase reporter assay of E4BP4 30 UTR. Construction of reporter and
mutant plasmids and luciferase assay were performed by Landbiology (Guangzhou,
China). For E4BP4 30 UTR reporter, a pair of reporter plasmids was constructed
with the SBS in E4BP4 30 UTR or its mutant by inserting the following oligos
(E4BP4XhoIF: 50-ccgctcgagATGGCTGCTGACCGAGCTATGC-30 and
E4BP4NotIR:50-ataagaatgcggccgcTGTGCTTGCCACCAATCCTTT-30) or
(mut-E4BP4_F:50-GATGCCCTCACTCTGCCTGGCGTGTAAATTTGGGGCCC
CCCACAGAGGCTGTACATACT-30 and mut-E4BP4_R:50-AGTATGTACAGCC
TCTGTGGGGGGCCCCAAATTTACACGCCAGGCAGAGTGAGGGCATC-30)
into the psiCHECK-2 vector. In addition, a pair of overexpression plasmids was
constructed with the complete cds of Smad3 (GI:2564492) or its mutant with the
deletion of exon 8 by amplifying our Smad3 full-length pcDNA3.0 plasmid with
the following primers: (mut-Smad3_F:50-TGGGTTCCCCCAGCATCCGCTGTTC
CGTGTAGAGACACTGGGAGTAAAGGGATCGGGT-30 and mut-Smad3_R:
50-ACCCGATCCCTTTACTCCCAGTGTCTCTACACGGAACAGCGGATGCT
GGGGGAACCCA-30).
For dual luciferase reporter assay (Promega), the E4BP4 luciferase reporter
plasmids and Smad3 plasmids were co-transfected into 293T cells. The
luminescence in lysates of harvested cells was measured at 48 h according to the
manufacturer’s instructions. The luciferase activity (M1) and Renilla luciferase
activity (M2) were measured by GloMax-Multi Detection System (Promega). The
reporter activity was represented by the ratio of M1/M2, which was the normalized
luciferase activity of the experimental plasmid (pGL4-basic; Promega). Results are
shown as mean±s.d. fold induction of luciferase in at least three independent
experiments.
Statistical analysis. Statistical analysis of the differences in MTT assay, tumour
volume, tumour weight, photon intensity, ratios of tumour nodules and positive
cells, protein and mRNA expression levels, dual luciferase reporter assay and
NK cell cytotoxicity were performed using analysis of variance, followed by
Newman–Keuls Post Test from the Prism Program (Prism 5.0 GraphPad Software,
San Diego, CA). Survival rates were generated based on the Kaplan–Meier method
and statistical signiﬁcance was determined by the log-rank test, P valueo0.05 was
considered statistically signiﬁcant.
Data availability. All data are available within the article, as ﬁgure source data or
Supplementary Information Files, or from the authors upon reasonable request.
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